Consistent with these findings, our data demonstrate that neutralizing antibodies against S100A8 improve colitis damage in DSS-treated Rnf128−/− mice, highlighting the importance of the RNF128‒S100A8 axis in macrophages for the development of therapeutic approaches for IBD. This evidence concerns the gene S100A8 and inflammatory bowel disease.